Brown's staff has requested a meeting with Allergan representatives to press them about the transaction. Allergan said on Sept. 8 it will transfer patents relating to its dry-eye medicine Restasis to the Saint Regis Mohawk Tribe, which will exclusively license them back to the company in exchange for ongoing payments.
The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.
Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.
Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.
(Reuters) - A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company's patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition.
Jim Cramer rattles off his take on callers' favorite stocks, including one hurting pharmaceutical name.
Aerie (AERI) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Remember when several months ago the news that David Tepper disclosed that his Appaloosa bought a (tiny 100,000 share) take in Snapchat in Q1, sending the stock briefly higher, especially after he said that he would add more if the price fell below its IPO price of $17? Well, according to his just released 13F, he didn't, and in fact has since dissolved his entire stake in the company that has since pivoted to dancing hotdogs. That triviality aside, what was most notable about Tapper's Q2 holdings is that in addition to boosting several key tech names, as well as opening a new $500+ million position in Alibaba, he took his total long equity holdings to just over $6.7 billion as of June 30, up from $6.1 billion at the end of March, the highest net long exposure since September 2014. Here is a breakdown of the key position changes for Tepper as of March 31: Top new positions: Alibaba, QQQ ETF, IBB ETF, Dollar General, Stryker, Energy Transfer Equity, L Brands, Wells Fargo, Cemex, Top exits: Regions Financial, Pfizer, Mylan, Teva, Symantec, Charter, ArcelorMittal, United Continental, TerraForm, US Steel Boosted stakes: Micron, Google, Western Digital, Facebook, Apple, United Rentals, Thermo Fisher, UnitedHealth Group, Delta Airlines Cut stakes: Southwest, General Motors, Allergan, Kinder Morgan, Williams Partners, HCA, Nucor Steel, Boston Scientific, Mohawk Industries, PNC Financial And the full visual summary: bold are additions; green are new positions; Red are exits.
M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks
Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
We issued an updated research report on Allergan plc (AGN) on Jun 23.